HealthQuill Pharma
Biogen Inc. and its Japanese partner, Eisai Co. Ltd., announced that the US regulator had approved four-weekly maintenance dosing for its Alzheimer's drug.
Drugs Health Medical Pharma

Biogen-Eisai’s Alzheimer’s drug gets 4-weekly dosing nod in US

Biogen Inc. and its Japanese partner, Eisai Co. Ltd., announced that the US regulator had approved four-weekly maintenance dosing for its Alzheimer's drug.

Read More
Britain's AstraZeneca will invest $3.5 billion in the US, its largest market, to expand its research and manufacturing footprint by the end of 2026, according to a company statement.
Drugs Pharma

AstraZeneca to invest $570 million in Canada to boost innovation, clinical delivery

HQ Team January 26, 2025: Pharmaceutical giant AstraZeneca has announced plans to invest US$570 million in Canada over the next decade, positioning the.

Read More
Hyundai ADM Bio, a subsidiary of South Korea’s Hyundai Bioscience, unveiled an oral cancer drug that allows patients to make a shift from intravenous chemotherapy.
Health Medical Pharma

South Korea’s Hyundai ADM unveils oral chemotherapy drug

Hyundai ADM Bio, a subsidiary of South Korea’s Hyundai Bioscience, unveiled an oral cancer drug that allows patients to make a shift from intravenous.

Read More
The US drug regulator has issued its most prominent warning on the use of certain drugs to treat multiple sclerosis, saying it may cause hospitalisation and death due to a “rare but serious” allergic reaction.
Drugs Health Medical Pharma

US drug regulator issues warning on certain multiple sclerosis drugs

The US drug regulator has issued its most prominent warning on the use of certain drugs to treat multiple sclerosis, saying it may.

Read More
The US drug regulator has put a clinical hold on Atara Biotherapeutics’ T-cell therapies for cancer and autoimmune diseases after issues were observed at a third-party manufacturing facility.
Drugs Health Medical Pharma

FDA places Atara’s Biothearapeutics’ cancer, autoimmune therapies on hold

The US drug regulator has put a clinical hold on Atara Biotherapeutics’ T-cell therapies for cancer and autoimmune diseases after issues were observed.

Read More
Daiichi Sankyo, the second-largest pharmaceutical company in Japan in terms of revenue, has set up a laboratory in the US for robotic development, automation and software.
Drugs Health Pharma

Daiichi Sankyo sets up robotic lab in US to speed up drug discovery

Daiichi Sankyo, the second-largest pharmaceutical company in Japan in terms of revenue, has set up a laboratory in the US for robotic development,.

Read More
GLP-1 based weight-loss drugs have some therapeutic benefits, but the risks are as high
Drugs Pharma Research

New insights on GLP-1 drugs: Benefits and risks unveiled

HQ Team January 21, 2024: The popular diabetes drugs, glucagon-like peptide-1 (GLP-1) receptor agonists such as Ozempic, have gained immense popularity for their.

Read More
The US, the World Health Organization’s top donor, has decided to withdraw from the global health body, accusing it of “mishandling” the Covid-19 pandemic.
Health Medical Pharma

US to withdraw from WHO after an executive order from Donald Trump

The US, the World Health Organization’s top donor, has decided to withdraw from the global health body, accusing it of “mishandling” the Covid-19.

Read More
AstraZeneca Plc.’s antibody-drug conjugate for treating a certain type of breast cancer got approval from the US drug regulator, the company stated.
Drugs Health Pharma

AstraZeneca’s medicine to treat a type of breast cancer gets US nod

AstraZeneca Plc.’s antibody-drug conjugate for treating a certain type of breast cancer got approval from the US drug regulator, the company stated.

Read More
Atara Biotherapeutics’ Ebvallotm therapy, for treating patients with a rare cancer that occurs after stem cell transplantation, got rejected by the US drug regulator.
Drugs Health Pharma

US drug regulator rejects Atara Biotherapeutics’ rare cancer therapy

Atara Biotherapeutics’ Ebvallotm therapy, for treating patients with a rare cancer that occurs after stem cell transplantation, got rejected by the US drug.

Read More